- Research article
- Open Access
GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma
Journal of Orthopaedic Surgery and Research volume 16, Article number: 713 (2021)
G2 and S phase-expressed-1 (GTSE1) negatively regulates the tumor-suppressive protein p53 and is potentially correlated with chemoresistance of cancer cells. This study aims to explore the effect of GTSE1 on the DNA damage repair and cisplatin (CDDP) resistance in osteosarcoma (OS).
Materials and methods
Expression of GTSE1 in OS was predicted in bioinformatics system GEPIA and then validated in clinically obtained tissues and acquired cell lines using RT-qPCR, immunohistochemical staining, and western blot assays. Gain- and loss-of-function studies of GTSE1 were performed in MG-63 and 143B cells to examine its function in cell cycle progression, DNA replication, and CDDP resistance. Stably transfected MG-63 cells were administrated into mice, followed by CDDP treatment to detect the role of GTSE1 in CDDP resistance in vivo.
GTSE1 was highly expressed in patients with OS and correlated with poor survival according to the bioinformatics predictions. Elevated GTSE1 expression was detected in OS tissues and cell lines. GTSE1 silencing reduced S/G2 transition and DNA replication, and it increased the CDDP sensitivity and decreased the expression of DNA repair-related biomarkers in MG-63 cells. GTSE1 overexpression in 143B cells led to inverse trends. In vivo, downregulation of GTSE1 strengthened the treating effect of CDDP and significantly repressed growth of xenograft tumors in nude mice. However, overexpression of GTSE1 blocked the anti-tumor effect of CDDP.
This study demonstrates that GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in OS.
Osteosarcoma (OS), characterized by high recurrence and metastasis rates, is the most common primary bone tumor that predominately affects children, adolescents, and young adults, and advanced patients with metastasis share an unfavorable prognosis . OS is likely to occur in the long bones, mainly including distal femur (43%), proximal tibia (23%), and humerus (10%), which are sites providing the most proliferative plates [2, 3]. Within these long bones, the tumor is commonly (90%) located in the metaphysis and appears as a palpable mass which is related with severe pain that is intense enough to wake patients from sleep [4, 5].
The current conventional treatments, including surgical resection and adjuvant chemotherapy, have improved the survival probability of patients, but the 5-year survival rate of patients with metastatic and recurrent disease remains unsatisfactory [5, 6]. Introduction of chemotherapy regimens such as cisplatin (CDDP), methotrexate, and doxorubicin significantly elevated prognosis for patients with localized OS [5, 7]. However, the survival rate has not improved during the past 2 decades , mainly owing to the acquired resistance of patients to chemotherapy [9, 10]. The chemotherapies induce DNA damages either directly (CDDP) or indirectly (doxorubicin) . Resistance mechanisms of DNA damage can lead to OS chemotherapy unresponsiveness, and therefore, overcoming DNA damage repair may enhance the sensitivity of tumor cells to chemo-drugs and enhance the treating outcome.
G2 and S phase-expressed-1 (GTSE1) is a p53-inducible gene located in chromosome 22q13.2-q13.3 and is specifically expressed in the S and G2 phases of the cell cycle [12, 13]. GTSE1 co-localizes with tubulin or microtubules and regulates microtubule dynamics by suppressing the microtubule depolymerase MCAK, which is fundamental for chromosome stability and alignment and spindle integrity during mitosis . Besides, GTSE1 can also negatively regulate nuclear accumulation and promote cytoplasmic localization and degradation of p53 owing to its nucleocytoplasmic shuttling ability [12, 15]. GTSE1 accumulates in the nucleus in response to DNA damage and downregulates p53, which allows cells to avoid apoptosis and promotes the G2/M transition, resulting in tumor development [16, 17]. GTSE1 has been reported to confer CDDP resistance to gastric cancer cells through inhibiting the p53 signaling . Increased expression of GTSE1 was found in several human malignancies, such as lung cancer , breast carcinoma , and hepatocellular carcinoma  and was correlated with unfavorable prognosis. However, the GTSE1 expression in OS and its link with drug resistance remain unexplored. This study intended to explore the function of GTSE1 in DNA damage and CDDP resistance in OS.
Materials and methods
OS tissues and the paired adjacent normal tissues were collected from 15 patients treated at the First Affiliated Hospital of Sun Yat-Sen University from November 2018 to May 2020. There were 9 males and 6 females, all of which were diagnosed as OS for the first time and without a history of radio- or chemo-therapy. The tissue samples were collected during surgery, immediately frozen in liquid nitrogen, and stored at − 80 °C until further use. This research was performed with the approval of Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University and in compliance with the Declaration of Helsinki. Each eligible participant signed the informed consent.
An osteoblast cell line hFOB 1.19 (CRL-11372) and four OS cell lines MNNG (CRL-1547), MG-63 (CRL-1427), 143B (CRL-8303), and SaOS-2 (HTB-85) were acquired from American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator at 37 °C with 5% CO2. The medium was renewed every 2 days.
Short hairpin (sh) RNA and overexpression vector of GTSE1 (sh-GTSE1; oe-GTSE1), and the negative control (NC) vectors (sh-NC and oe-NC) were all procured from RiboBio Co., Ltd. (Guangzhou, Guangdong China). MG-63 cells were transfected with sh-GTSE1 or sh-NC, and 143B cells were transfected with oe-NC or oe-GTSE1 for in vitro experiments. MG-63 cells transfected with oe-GTSE1, sh-GTSE1, and empty vector (EV) were used for in vivo experiments. All transfections were conducted using the lipofectamine 2000 kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). Stably transfected cells were screened using 2 μg/mL puromycin (Sigma-Aldrich, St Louis, MO, USA). Successfully transfected cells were cultured in DMEM at 37 °C with 5% CO2 for subsequent use.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA from OS and normal tissues or cells was isolated by the TRIzol reagent (Thermo Fisher Scientific). Complementary DNA (cDNA) was synthesized using a Primescript RT kit (Takara Holdings Inc., Kyoto, Japan). Expression of GTSE1, EXO1, PLK4, and RFC4 mRNA was detected using the FastStart PCR master mix (Roche Ltd., Basel, Switzerland). The ABI Prism 7500 System (Life Technologies, Gaithersburg, MD, USA) was used for data collection and quantification analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous loading. The primer sequences are listed in Table 1.
Western blot analysis
Cells (1 × 106) were lysed in RIPA lysis buffer (Solarbio Science & Technology Co., Ltd., Beijing, China) to collect total protein, and the protein concentration was examined using a bicinchoninic acid kit (Keygen Biotech Co., Ltd., Nanjing, Jiangsu, China) according to the instructions. An equal amount (60 μg) of protein sample was run on 12% SDS-PAGE and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). After being blocked in 5% not-fat milk for 1 h, the membranes were hybridized with the primary antibodies GAPDH (1: 10,000, ab181602, Abcam), GTSE1 (1:1000, GTX66223, GeneTex, CA, USA), Cyclin D1 (1:1000, #2978S, Cell Signaling Technology (CST), Beverly, MA, USA), Cyclin E1 (1:1000, #20808S, CST), proliferating cell nuclear antigen (PCNA; 1:1000, #13110S), cleaved caspase 3 (1:500, ab32042), Bax (1:1000, GTX109683, GeneTex), γH2AX (1:5000, ab81299), and DNA-PKcs (1:1000, ab32566) at 4 °C overnight, and then with HRP-conjugated secondary antibody (1:5000, ab205718, Abcam Inc., Cambridge, MA, USA) at room temperature for 1 h. The protein bands were developed using the ECL reagent (Pierce, Rockford, IL, USA).
Cell cycle analysis
After transfection, the cells (1 × 106) were washed with phosphate-buffered saline (PBS) and fixed with 70% ethanol at 4 °C overnight. All samples were treated with 5 μL RNase A and 450 μL propidium iodide (PI, Keygen) in the dark at 22 °C for 1 h. The cell cycle distribution was analyzed by a flow cytometer (Applied Biosystems, Inc., Carlsbad, CA, USA).
5-Ethynyl-2ʹ-deoxyuridine (EdU) labeling assay
Proliferation activity of the cells was examined using an EdU labeling kit (RiboBio Co., Ltd., Guangzhou, Guangdong, China). In brief, MG-63 and 143B cells were seeded in 24-well plates (5 × 105 cells per well) for 24 h and incubated with 50 μM EdU for 2 h. Cells were washed in PBS, fixed with 4% paraformaldehyde (PFA) for 30 min, penetrated in 0.5% Triton X-100 for 10 min, treated with 200 μL 1 × Apollo reaction mixture in the dark for 30 min, and finally treated with 200 μL 1 × Hoechst 33,342 for 30 min. The staining was observed under a fluorescence microscope (Olympus Optical Co., Ltd, Tokyo, Japan). Positively stained cells were counted under 5 random fields of views.
Flow cytometry for cell apoptosis
Apoptosis of cells was examined using an Annexin V-fluorescein isothiocyanate (FITC)/PI kit (Invitrogen, Thermo Fisher Scientific). In short, the OS cells (1 × 106) were washed with cold PBS and resuspended in 400 μL Annexin V-FITC binding buffer, and then stained with 5 μL Annexin V-FITC and 10 μL PI at 22 °C in the dark for 15 min. The FITC and PI fluorescence was examined using the flow cytometer. The apoptosis of cells was examined using the CellQuest software (BD Biosciences).
Cell activity examination
MG-63 cells were allocated into Control group, sh-NC group, and sh-GTSE1 group, and 143B cells were allocated into oe-NC and oe-GTSE1 groups after corresponding transfections. The cells were seeded on 96-well plates at 5000 cells per well. After cell adherence, cells were treated with CDDP (Qilu Pharmaceutical Co., Ltd., Shandong) at different doses (0, 1, 2, 3, 4, and 5 μg/mL). After 24 h, each well was loaded with 10 μL cell counting kit-8 (CCK-8) reagent (BestBio, Shanghai, China) for 2 h of incubation at 37 °C. The optical density (OD) at 450 nm was determined using a microplate reader (EMax Plus, Molecular Devices, CA, USA). The 50% inhibitory concentration (IC50) was examined using the GraphPad Prism 5 software.
Xenograft tumors in nude mice
MG-63 cells transfected with sh-GTSE1, oe-GTSE1, or EV were used for in vivo experiments. Twenty-four female BALB/c nude mice (3–4 weeks old, 15.5 ± 2.4 g) were procured from Laboratory Animal Center of Chinese Academy of Sciences (Shanghai, China). The animals were housed in specific-pathogen-free grade animal rooms in a 12-h dark/light cycle with free access to food and drinking water. After one week of acclimation, the mice were allocated into four groups (EV + PBS group, EV + CDDP group, sh-GTSE1 + CDDP group, and oe-GTSE1 + CDDP group), 6 in each. In the EV + PBS group, mice were subcutaneously injected with MG-63 cells (1 × 106) transfected with EV and intraperitoneally injected with PBS weekly. In the EV + CDDP group, mice were subcutaneously injected with MG-63 cells (1 × 106) transfected with EV and intraperitoneally injected with CDDP (3 mg/kg) weekly. In the sh-GTSE1 + CDDP group, mice were subcutaneously injected with MG-63 cells (1 × 106) transfected with sh-GTSE1 and intraperitoneally injected with CDDP (3 mg/kg) weekly. In the oe-GTSE1 + CDDP group, mice were subcutaneously injected with MG-63 cells (1 × 106) transfected with oe-GTSE1 and intraperitoneally injected with CDDP (3 mg/kg) weekly. After cell transplantation, the volume (V) of xenograft tumors was examined weekly as follows: V = a × b2/2, in which “a” refers to the length and “b” refers to the width. After 4 weeks, the mice were euthanized with 1% pentobarbital sodium (150 mg/kg) to collect the tumor tissues for weighing and histological examination. Animal procedures were approved by the Animal Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University and performed with the Guide for the Care and Use of Laboratory Animals (NIH, Bethesda, Maryland, USA).
Immunohistochemical (IHC) staining
Collected tissue samples were fixed with 4% PFA, embedded in paraffin, and cut into 4-μm slices. The slices were dewaxed in xylene and rehydrated in ethanol, treated with 3% H2O2 to block the activity of endogenous peroxidases, and treated with citrate buffer for antigen retrieval. After that, the slices were then treated with normal goat serum and incubated with antibodies against GTSE1 (1:500, ab272670, Abcam), Ki-67 (1:100, 14-5698-82, Thermo Fisher Scientific) overnight at 4 °C and treated with the goat anti-rabbit IgG (1:2000, ab205718, Abcam) at room temperature for 1 h. The slices were incubated with 40 μL HRP-labeled streptavidin working solution at 37 °C for 15 min. The staining was developed using DAB, and the slices were counter-stained with hematoxylin, rehydrated in alcohol, sealed with neutral balsam, and observed under the microscope. The number of GTSE1- or Ki-67-positive cells was counted under the microscope with five random fields included.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)
The tumor tissues were cut into 4-μm slices and labeled according to the instructions of a TUNEL kit (Roche, Indianapolis, IN, USA). In brief, the slices were routinely dewaxed, rehydrated, and permeabilized. After that, the slices were added with 20 mg/L protease K solution for 15 min and 500 μL TUNEL reaction mixture for 1 h of reaction in a wet box in the dark. Next, the slices were added with 50 μL converter-POD for 30 min reaction in the wet box. Thereafter, 100 μL DAB was added for a 10-min incubation. The slices were counter-stained with hematoxylin and observed under the microscope (Nikon Instruments Inc., Tokyo, Japan). The apoptosis rate in tissues was determined as follows: rate = number of apoptotic tissues/total cells.
For each experiment, at least three repetitions were performed. Statistical analysis was conducted by SPSS 20.0 (IBM Corp. Armonk, NY, USA) and GraphPad Prism 8.02 (GraphPad Software, CA). Data were exhibited as the mean ± standard deviation (SD). Differences were analyzed by the paired or unpaired t test (two groups), or by one- or two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test (over two groups). p < 0.05 was considered to show statistical analysis.
GTSE1 is highly expressed in OS and possibly correlated with unfavorable outcome
The expression profiling of GTSE1 in OS was first obtained in Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/detail.php), a web-based tool to deliver fast and customizable functionalities based on tremendous amount of RNA sequencing data from large consortium projects such as the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) . The GEPIA data suggested that GTSE1 was highly expressed in patients with sarcoma (Fig. 1A). In the clinical tissue samples, GTSE1 expression was elevated in OS tumor tissues relative to the adjacent tissues according to RT-qPCR and IHC staining assays (Fig. 1B, C). A similar trend was identified in the acquired cell lines where increased mRNA and protein expression of GTSE1 was detected in four OS cell lines compared to the normal hFOB 1.19 cells (Fig. 1D, E). In addition, data in GEPIA suggested that high expression of GTSE1 in patients with OS was correlated with reduced survival probability and increased risk of recurrence (Fig. 1F, G).
GTSE1 promotes S/G2 transition and DNA replication in OS cells
According to the results in Fig. 1E, MG-63 cells with the highest GTSE1 expression were transfected with sh-GTSE1, whereas 143B cells with the lowest GTSE1 expression among the four OS cell lines were transfected with oe-GTSE1 for gain- and loss-of-function studies in vitro. The successful transfections were validated by RT-qPCR (Fig. 2A). Flow cytometry on cell cycle distribution suggested that knockdown of GTSE1 in MG-63 cells increased the number of cells at S phase but reduced the number of cells at G2 phase, indicating that GTSE1 silencing blocked the S/G2 transition in MG-63 cells (Fig. 2B). By contrast, overexpression of GTSE1 reduced the portion of 143B cells at S phase and increased the portion of cells at G2 phase (Fig. 2C). In the molecular perspective, downregulation of GTSE1 in MG-63 cells reduced the expression of S/G2 transition-related factors, including Cyclin D1 and Cyclin E1 and it also reduced the expression of DNA replication-related factor PCNA in cells (Fig. 2D). As expected, inverse results were found in 143B cells where GTSE1 was upregulated (Fig. 2E). The function of GTSE1 in DNA replication of cells was examined by the EdU labeling assay. It was indicated that silencing of GTSE1 reduced the number of EdU-positive (DNA replicating) MG-63 cells, whereas overexpression of GTSE1 increased the number EdU-positive 143B cells (Fig. 2F, G). These results indicated that GTSE1 is crucial for the S/G2 transition and DNA replication in OS cells.
GTSE1 is correlated with CDDP sensitivity of OS cells
To determine whether the GTSE1 expression is correlated with the CDDP resistance of OS cells, MG-63 cells transfected with sh-GTSE1 and sh-NC, and 143B cells transfected with oe-GTSE1 and oe-NC transfected were treated with different doses of CDDP. After 48 h, the IC50 value of CDDP was determined by the CCK-8 method. The IC50 value of CDDP in the Control group (without any transfection) was 2.89 μg/mL, and that in the sh-NC and sh-GTSE1 groups was 2.77 μg/mL and 1.54 μg/mL, respectively. By contrast, the IC50 value of CDDP in the oe-NC and oe-GTSE1 groups was 2.59 and 6.81, respectively (Fig. 3A, B). These results indicated that silencing of GTSE1 significantly reduced the IC50 value of CDDP, namely elevated the CDDP sensitivity of MG-63 cells, and overexpression of GTSE1 decreased the CDDP sensitivity of 143B cells. Next, cells in each group were treated with CDDP at 3 μg/mL for 48 h, and flow cytometry was performed to analysis cell apoptosis. Of note, GTSE1 downregulation significantly elevated cell apoptosis induced by CDDP. However, GTSE1 overexpression decreased apoptosis rate of 143B following CDDP treatment, indicating that GTSE1 increased the resistance of cells to CDDP (Fig. 3C). Western blot analysis on cell apoptosis-related factors indicated that silencing of GTSE1 significantly increased the expression of pro-apoptotic proteins cleaved caspase3 and Bax but reduced the expression of anti-apoptotic Bcl-2 in MG-63 cells. Still, overexpression of GTSE1 suppressed the levels of cleaved caspase3 and Bax but increased the level of Bcl-1 in 143B cells (Fig. 3D). These results, collectively, suggested that GTSE1 knockdown increases CDDP sensitivity in OS cells.
GTSE1 enhances DNA damage repair-related biomarkers in OS cells and reduces CDDP-induced cell apoptosis
The findings above indicated that GTSE1 is possibly necessary for DNA replication and CDDP resistance in OS cells. To validate this, MG-63 cells transfected with sh-GTSE1 and 143B cells transfected with oe-GTSE1 were treated with CDDP (3 μg/mL) to induce DNA damage. After that, the levels of γH2AX, a DNA double-strand break biomarker, and DNA-PKcs, a DNA damage repair biomarker, were determined using western blot analysis. After 48 h of CDDP treatment, the expression of γH2AX in MG-63 cells was significantly elevated, but the expression of DNA-PKcs was reduced (Fig. 4A). However, overexpression of GTSE1 led to an increase in DNA-PKcs while a decline in γH2AX in 143B cells (Fig. 4B), indicating that GTSE1 is possibly correlated with DNA damage repair in OS cells. Meanwhile, silencing of GTSE1 reduced the expression of DNA repair-related factors EXO1, PLK4, and RFC4 in MG-63 cells (Fig. 4C), and overexpression of GTSE1 led to inverse trends in 143B cells again (Fig. 4D).
GTSE1 affects tumorigenesis of OS cells in nude mice following CDDP treatment
The function of GTSE1 in CDDP resistance in OS was further examined in vivo. To avoid unnecessary animal death, only MG-63A cells with the highest expression of GTSE1 were used for animal experiments. GTSE1 stably transfected with oe-GTSE1 or sh-GTSE1 were injected into the right flank of nude mice, followed by PBS or CDDP treatment. Compared to PBS treatment, injection of CDDP significantly reduced growth of xenograft tumors in nude mice. Silencing of GTSE1 strengthened, whereas overexpression of GTSE1 blocked the tumor-eliminating function of CDDP in nude mice (Fig. 5A,B). The IHC staining of Ki-67 (a proliferation marker) indicated that silencing of GTSE1 led to a further decline in Ki-67 expression, whereas overexpression of GTSE1 restored the Ki-67 expression in xenograft tumors of mice following CDDP treatment (Fig. 5C,D). The cell apoptosis in the xenograft tumors was examined by TUNEL assay. It was observed that CDDP treatment induced cell apoptosis in the xenograft tumors. Downregulation of GTSE1 further promoted, whereas overexpression of GTSE1 reduced cell apoptosis in the xenograft tumor tissues (Fig. 5E).
The bone microenvironment is a complex biological system and an ideal fertile soil which facilitates the onset and development of both primary and secondary tumors . The survival of patients largely benefited from the advance in chemotherapy, but chemoresistance frequently occurs, leading to treatment failure . In this study, the authors report that the cell cycle-related gene GTSE1 is possibly correlated with activation of the DNA damage repair signaling and reduced treating effect of CDDP on OS.
The expression profiling of GTSE1 in OS has never been mentioned previously, though its high expression has been identified in several malignancies [17, 19,20,21, 24]. The bioinformatics data indicated that GTSE1 was highly expressed in OS and correlated with unfavorable prognosis of patients. High GTSE1 expression was then detected in clinically collected OS tissues and the procured OS cell lines, preliminarily indicating its involvement in cancer progression. Intriguingly, GTSE1 overexpression has been reported to delay the transition of the G2 to M phase . Likewise, a study by Fen Lin et al. suggested that downregulation of GTSE1 increased the portion of breast cancer cells in the S phase, whereas GTSE1 upregulation led to a delay in the M/G2 transition . In agreement with this, in the present study, downregulation of GTSE1 increased the number of MG-63 cells in the S phase while upregulation of GTSE1 increased the number of cells in the G2 phages, suggesting that GTSE1 is crucial for the S/G2 transition in OS cells. A recent study by Xiong et al. demonstrated that high expression of GTSE1 was mainly enriched in the cell cycle, DNA replication, and p53 signaling pathways in prostate cancer . GTSE1 has also been reported to play a tumor-promoting role through triggering cell proliferation . In this paper, the EdU labeling assay indicated that overexpression of GTSE1 augmented the DNA replication ability of OS cells. Collectively, these findings elucidated the oncogenic role or GTSE1 in OS.
DNA repair and apoptosis resistance has been well-established as one of the mechanisms, leading to drug resistance . CDDP represents one of the major DNA damaging drugs in the treatment of OS . It cross-links with nuclear DNA to induce genomic DNA damage, and it can also cytotoxically lead to tumor cell apoptosis via the production of reactive oxygen species . As aforementioned, GTSE1 has been demonstrated to induce DNA damage impair and CDDP resistance by inhibiting the p53 signaling in gastric cancer . Importantly, in our experiments, downregulation of GTSE1 in MG-63 cells reduced the IC50 value of CDDP. Namely, it reduced the CDDP-resistance of the cancer cells. As a consequence, the apoptosis rate of cells was increased upon GTSE1 silencing. Overexpression of GTSE1 in 143B cells led to inverse trends. High expression of GTSE1 has been reported to be associated with reduced sensitivity of hepatocellular carcinoma cells to 5-fluorouracil . Likewise, upregulation of GTSE1 by other molecules was correlated with increased CDDP resistance in non-small cell lung cancer (NSCLC) . GTSE1-mediated stabilization of p21 conferred cell resistance to the microtubule cytotoxic paclitaxel . Moreover, in the present study, overexpression of GTSE1 increased the expression of the repair marker DNA-PKcs and the related factors including EXO1, PLK4, and RFC4, and it reduced the expression of DNA damage marker γH2AX in cells. Upon DNA damage, GTSE1 promotes cytoplasmic translocation and degradation of p53 and blocks its pro-apoptotic roles . Quite in agreement with our findings, GTSE1 upregulated γH2AX, whereas suppressed DNA-PKcs in NSCLC to counteract the DNA damage induced by irradiation . Moreover, the function of GTSE1 was further validated in vivo, where knockdown of GTSE1 reduced the volume and weight of xenograft tumors following CDDP treatment, whereas overexpression of GTSE1 blocked the tumor-eliminating role of CDDP.
In conclusion, this study demonstrates that GTSE1 plays an oncogenic role in OS whose high expression is possibly correlated with cell cycle progression and most importantly, the DNA damage repairs following CDDP treatment. This study may offer novel insights into the treatment of OS that concomitant inhibition of GTSE1 may strengthen the treating effects of CDDP or other DNA damage-related chemo-drugs.
Availability of data and materials
The data used to support the findings of this study are available from the corresponding author upon request.
Analysis of variance
Cell counting kit-8
Dulbecco’s modified Eagle’s medium
Fetal bovine serum
G2 and S phase-expressed-1
50% Inhibitory concentration
- IHC staining:
- mean ± SD:
Mean ± standard deviation
Proliferating cell nuclear antigen
Polo-like kinase 4
Replication factor C subunit 4
Reverse transcription-quantitative polymerase chain reaction
Short hairpin RNA
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling
Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189–95. https://doi.org/10.1016/j.canlet.2016.11.019.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90. https://doi.org/10.1200/JCO.2002.20.3.776.
Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017;405:90–9. https://doi.org/10.1016/j.canlet.2017.07.024.
Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J, Rodriguez R. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci. 2015;72:3097–113. https://doi.org/10.1007/s00018-015-1918-y.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35. https://doi.org/10.1200/JCO.2014.59.4895.
Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, Gonzalez MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016;2016:3631764. https://doi.org/10.1155/2016/3631764.
Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, Qian A. Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21196985.
Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012;2012: 704872. https://doi.org/10.1155/2012/704872.
Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Muller C, Tienghi A, Wiebe T, Comandone A, Bohling T, Del Prever AB, Brosjo O, Bacci G, Saeter G, Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–52. https://doi.org/10.1200/JCO.2004.00.5785.
Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21186885.
Fanelli M, Tavanti E, Patrizio MP, Vella S, Fernandez-Ramos A, Magagnoli F, Luppi S, Hattinger CM, Serra M. Cisplatin resistance in osteosarcoma: in vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatments. Front Oncol. 2020;10:331. https://doi.org/10.3389/fonc.2020.00331.
Collavin L, Monte M, Verardo R, Pfleger C, Schneider C. Cell-cycle regulation of the p53-inducible gene B99. FEBS Lett. 2000;481:57–62. https://doi.org/10.1016/s0014-5793(00)01969-4.
Monte M, Collavin L, Lazarevic D, Utrera R, Dragani TA, Schneider C. Cloning, chromosome mapping and functional characterization of a human homologue of murine gtse-1 (B99) gene. Gene. 2000;254:229–36. https://doi.org/10.1016/s0378-1119(00)00260-2.
Bendre S, Rondelet A, Hall C, Schmidt N, Lin YC, Brouhard GJ, Bird AW. GTSE1 tunes microtubule stability for chromosome alignment and segregation by inhibiting the microtubule depolymerase MCAK. J Cell Biol. 2016;215:631–47. https://doi.org/10.1083/jcb.201606081.
Monte M, Benetti R, Collavin L, Marchionni L, Del Sal G, Schneider C. hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem. 2004;279:11744–52. https://doi.org/10.1074/jbc.M311123200.
Monte M, Benetti R, Buscemi G, Sandy P, Del Sal G, Schneider C. The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem. 2003;278:30356–64. https://doi.org/10.1074/jbc.M302902200.
Xu T, Ma M, Chi Z, Si L, Sheng X, Cui C, Dai J, Yu S, Yan J, Yu H, Wu X, Tang H, Yu J, Kong Y, Guo J. High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. Cancer Sci. 2018;109:1787–98. https://doi.org/10.1111/cas.13607.
Subhash VV, Tan SH, Tan WL, Yeo MS, Xie C, Wong FY, Kiat ZY, Lim R, Yong WP. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer. 2015;15:550. https://doi.org/10.1186/s12885-015-1550-0.
Zhang C, Min L, Zhang L, Ma Y, Yang Y, Shou C. Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer. Tumour Biol. 2016;37:2193–207. https://doi.org/10.1007/s13277-015-3938-5.
Canevari RA, Marchi FA, Domingues MA, de Andrade VP, Caldeira JR, Verjovski-Almeida S, Rogatto SR, Reis EM. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. Tumour Biol. 2016;37:13855–70. https://doi.org/10.1007/s13277-016-5133-8.
Guo L, Zhang S, Zhang B, Chen W, Li X, Zhang W, Zhou C, Zhang J, Ren N, Ye Q. Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells. Cell Biol Toxicol. 2016;32:263–74. https://doi.org/10.1007/s10565-016-9327-z.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102. https://doi.org/10.1093/nar/gkx247.
Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S, Guo Z. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res. 2018;37:201. https://doi.org/10.1186/s13046-018-0880-6.
Lei X, Du L, Zhang P, Ma N, Liang Y, Han Y, Qu B. Knockdown GTSE1 enhances radiosensitivity in non-small-cell lung cancer through DNA damage repair pathway. J Cell Mol Med. 2020;24:5162–7. https://doi.org/10.1111/jcmm.15165.
Utrera R, Collavin L, Lazarevic D, Delia D, Schneider C. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J. 1998;17:5015–25. https://doi.org/10.1093/emboj/17.17.5015.
Lin F, Xie YJ, Zhang XK, Huang TJ, Xu HF, Mei Y, Liang H, Hu H, Lin ST, Luo FF, Lang YH, Peng LX, Qian CN, Huang BJ. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner. J Exp Clin Cancer Res. 2019;38:152. https://doi.org/10.1186/s13046-019-1157-4.
Xiong J, Zhang J, Li H. Identification of G2 and S phase-expressed-1 as a potential biomarker in patients with prostate cancer. Cancer Manag Res. 2020;12:9259–69. https://doi.org/10.2147/CMAR.S272795.
Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014;355:10–20. https://doi.org/10.1016/j.jtbi.2014.02.025.
Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Dev Ther. 2016;10:1885–95. https://doi.org/10.2147/DDDT.S106412.
Wu X, Wang H, Lian Y, Chen L, Gu L, Wang J, Huang Y, Deng M, Gao Z, Huang Y. GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis. Sci Rep. 2017;7:5129. https://doi.org/10.1038/s41598-017-05311-2.
Liu B, Pan CF, Ma T, Wang J, Yao GL, Wei K, Chen YJ. Long noncoding RNA AK001796 contributes to cisplatin resistance of nonsmall cell lung cancer. Mol Med Rep. 2017;16:4107–12. https://doi.org/10.3892/mmr.2017.7081.
Bublik DR, Scolz M, Triolo G, Monte M, Schneider C. Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. J Biol Chem. 2010;285:5274–81. https://doi.org/10.1074/jbc.M109.045948.
The authors are thankful to Health Public Welfare Scientific Research Project in Futian District of Shenzhen (No. FTWS2019017).
This work was supported by Health Public Welfare Scientific Research Project in Futian District of Shenzhen (No. FTWS2019017).
Ethics approval and consent to participate
This research was performed with the approval of Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University and in compliance with the Declaration of Helsinki. Each eligible participant signed the informed consent. Animal procedures were approved by the Animal Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University and performed with the Guide for the Care and Use of Laboratory Animals (NIH, Bethesda, Maryland, USA).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Xie, C., Xiang, W., Shen, H. et al. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma. J Orthop Surg Res 16, 713 (2021). https://doi.org/10.1186/s13018-021-02859-8
- DNA repair
- Drug resistance